Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't be on the sidelines when the Bunka Bomb drops, this thing will explode.
Brokers coming back from nappy time, we need some bargain hunters, push this thing back up and negate bearish shooting star candlestick forming on the chart!
Me too, I don't worry about the day to day fluctuations, I know this is just a tailgate party before the main event.
RSI is near extreme overbought, bringing out hoards of technical traders and profit traders, lucky to break even today.
Wow, a half a million shares in first 5 min, we used to be hard pressed to do that in a whole day!
Golden Cross
50 Day MA soon to cross 200 Day MA.
Extremely important edible rules favorable to Lexaria. If you don't have absorption tech. then your edible product just won't sell. Negotiations underway with 10+ producers!!
https://cannabisnow.com/new-cannabis-contraband-brands-products-now-outlawed-californias-new-rules/
No edibles stronger than 100 milligrams, no edible serving sizes bigger than 10 milligrams.
The biggest changes are to edibles, and one of the most significant limits is on serving sizes. Will we have to say goodbye to Slactavis’s 1500 mg bottles of syrup, 1000 mg bags of Bomb Chips, Kiva’s 180 mg chocolate bars, and Korova’s 300 mg popcorn bags? Quite possibly, yes.
According to the Bureau of Cannabis Control: “Beginning January 1, 2018, licensees shall not transport or sell any edible cannabis product that exceeds 10 milligrams per serving. Adult-use products may not exceed 100 milligrams per package; however, medicinal cannabis products may exceed 100 milligrams per package.”
Seems pretty clear-cut. At the same time, in the same breath, the bureau says it will allow retailers to “sell cannabis products that do not meet the THC limits per package established by the state Department of Public Health” during the six-month transition period.
Whether the edible dose limits drop on Jan. 1 or July 1, THC limits are a significant disruption to most dispensaries’ edibles menus, which are full of products much, much stronger than 100 mg. It appears that as long as products above 100 mg are sold on the medical cannabis market, and as long as they’re somehow clearly identified as products with many multiple serving sizes, they may be allowed. Don’t throw away your medical marijuana recommendation anytime soon — but it gets worse.
Lexaria does not say why trading is up
2017-12-08 13:11 ET - News Release
An anonymous director reports
LEXARIA ANNOUNCES NO MATERIAL DEVELOPMENTS
At the request of the Investment Industry Regulatory Organization of Canada, Lexaria Bioscience Corp. is not aware of any undisclosed material change to the corporation's business or operations and it has no material change to report at this time. Lexaria conducts technology licence sales activities as part of its everyday business activities and will disclose all material sales and licensing agreements if and as they occur.
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and outlicenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the United States and in Australia related to edible forms of cannabinoids. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
We seek Safe Harbor.
One thing that is driving it is the strict limits being put in place regarding the amount of THC that can be included in each portion of edibiles.
If your not using Lexaria's absorption technology your product is not going to have the same effect as say 1906's chocolates, when they both contain the same milligrams of THC.
Stock definitely has more room to run we're nowhere near being overbought on the RSI.
Looks like we're building a stairway to heaven!
$1.22 just fell in Canada. How come we always have to do the heavy lifting, EH!
Breakout!
We've just broken out from the apex of the triangle consolidation pattern we've been forming for the last couple of weeks. New up leg now underway!!!
"Tierra hasn’t provided a list of holdings."
I rather doubt that any company that can't show audited financials will be included, and we're still waiting. Looks like it will be another lost opportunity.
Seems like GRNH may have already been scooped in their cloning initiative by GB Sciences GBLX.
https://www.stockwatch.com/News/Item.aspx?bid=U-C2173-U%3aGBLX-20171205&symbol=GBLX®ion=U
If GBLX was on a Canadian exchange they would have made them put out a release explaining the reason for the increase in price and volume. Eh!
Obviously, this stock is in play, one or more big players are building a position.
1.75 million in one block!!!!!
Impressive! The largest one-day volume in history and the day is nowhere near done.
Is a major picking up 9.9% of shares prior to launching a takeover?
I'm showing 128,000,300 O/S.
Probably just day traders, they made 5 or 6 cents and now they're out.
Not everyone has a long-term outlook.
TurboCBD one of the most innovative!
https://hightimes.com/culture/innovative-cbd-products-checked-mj-bizcon/
Maybe it's not a conspiracy, and they just need some cash for Black Friday!
All I can say about those financials is, "they suck."
Only 2 board members? Haas and his lawyer! That's a great big red flag!
And who's getting all these millions of shares for consulting, a related party?
They're spending more on consulting than revenue, who in their right mind does that? And what are they consulting about GRNH isn't doing much of anything! They have one deal to build one greenhouse for a 100% owned subsidiary.
Wow! Pitiful!
As you well know the financials are being reviewed by an independent, 3rd party CPA. Also known as an audit.
I think he's talking about legalization in California.
They're coming to take us away! HA, HA!
http://www.thecannabist.co/2017/11/13/cannabis-industry-market-chris-burggraeve/92281/
Budweiser’s ex-marketing chief sees cannabis as the new craft beer
"The same way that craft beer started and, for the longest time, was ignored and then exploded, there's no reason why the same thing wouldn't happen in this space," said Chris Burggraeve
“This bud’s for you” has taken on a whole new meaning for Chris Burggraeve.
The former chief marketing officer for Anheuser-Busch InBev NV, the brewer of Budweiser beer, is moving from barley and hops to cannabis as the alcohol industry casts its sights on the burgeoning market for state-sanctioned marijuana.
Burggraeve, 52, has made two investments in the space. Most recently, he joined the advisory board of GreenRush Group. The San Francisco-based startup, which says it aims to be the Amazon of weed, closed its $3.6 million Series A fundraising round last week. Burggraeve, a native of Belgium with a master’s degree in economics, also co-founded Toast, which makes pre-rolled joints.
The former beer executive is one of many entrepreneurs and investors increasingly flocking to the cannabis industry from the traditional business world. Big Beer took its first step last month when Constellation Brands Inc., which sells Corona in the U.S., announced its investment in Canopy Growth Corp., a Canadian seller of medicinal-marijuana products. In Burggraeve’s view, that’s just the beginning.
“This is one of the fastest-growing categories globally,” he said. “Why? Because people want it. When consumers want something, you ignore it at your peril.”
Sixty-four percent of the U.S. population now wants to lift the federal ban on marijuana, according to a Gallup poll released last month. That’s the largest rating since the firm started asking about the topic in 1969, the year of the Woodstock music festival, when only 12 percent approved.
After leaving the corporate marketing world about five years ago, Burggraeve said he’s focused on teaching, consulting and investing in what he considers disruptive categories. Cannabis, he said, could shake up the large beer companies in the same manner that smaller, independent brewers did over the past 20 years.
“The same way that craft beer started and, for the longest time, was ignored and then exploded, there’s no reason why the same thing wouldn’t happen in this space,” he said. “There will be part supplementing and part complementing. The jury is out on how and where that will happen.”
Related stories
Florida Rep. Matt Gaetz: Stop punishing cannabis industry. Remove 280E from tax code.
California proposes coalition of marijuana states — and armored cars for tax cash
Public banks offer hope for cannabis industry
Michigan township sets up medical marijuana industrial park for growing, producing, testing
L.A. aims to help disadvantaged communities cash in on marijuana legalization
GreenRush is a technology platform that connects consumers, dispensaries and delivery people to bring pot to people’s doors. The company, which is live in California and Nevada, plans to expand to other states, including New York and Massachusetts.
The idea is to build up the business before marijuana is one day legal under federal law. Big companies like Amazon shy away from the industry now because of the federal ban.
Cannabis is legal for recreational use in eight states and the District of Columbia, including California. That means one in five American adults can ingest the drug however they please. Twenty-one additional states allow for medicinal use of the plant. The industry hit $6 billion in sales in 2016, a figure that is expected to reach $50 billion by 2026, according to Cowen & Co.
Still, investing in marijuana isn’t without risk. The Trump administration has sent mixed signals, though Attorney General Jeff Sessions is an ardent opponent of legalizing pot. And traditional banking institutions have largely stayed away, forcing most transactions to be conducted in cash.
Constellation may have broken the taboo. Companies may now find the risk worth it, according to Burggraeve. Otherwise, alcoholic beverage companies could find themselves falling behind.
“It will all merge and cross-fertilize and fuse — not because the companies want it, but because the consumers want it,” Burggraeve said.
The lesson from the Canopy/Lexaria examples is don’t let short term factors frighten you into reversing the one great call you have made. After all, “If you don’t profit from your own mistakes, someone else will.”
Ted Ohashi
As we reported in Let’s Toke Business on November 3, 2017, “Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) announced it has received a new Notice of Allow-ance from the United States Patent and Trademark Of-fice (USPTO) for the use of its technology as a delivery platform for all cannabinoids including THC…. Although LXRP stock is up significantly since the announcement, we have consistently extolled its investment virtues and it remains one of our favorites.” At the close prior to the release, LXRP closed at $.39 and one week later, the shares are in the $.68 range – almost a new high and a gain of over 75%.
Many investors who didn’t own Canopy Growth or Lexaria Bioscience lamented the fact they missed the boat - again. “I’m always unlucky,” bemoan some while others claim “Events like this are unpredictable.” But rather than lament the facts, it is a great time to remember that “those who don’t learn from history are doomed to relive it.”
These were both very predictable events. In fact, both were widely forecast.
In Let’s Toke Business April 1, 2016 after Philip Morris (NYSE: PM) invested in Israeli based cannabis com-pany Syqe Medical, we said “The importance is it gives us a glimpse at the investment endgame in marijuana, probably still years away. The tobacco and alcoholic beverage companies will buy up cannabis companies when appropriate.” We are not pointing this out to boast about how prescient we were because several others expressed the same idea. Many investors and their advisors foresaw what would happen in the future is the large tobacco, alcoholic beverage and pharmaceutical companies would take over the clear cut leaders in cannabis. The lesson is that many investors knew that part of Canopy Growth’s investment future included being bought into and eventually bought out by one of these big companies. It may not have been the main reason an investor bought Canopy and it may have happened sooner than expected but it was certainly one of the reasons.
In the November 4, 2016 Let’s Toke Business after Lexaria received its first U.S. patent we said, “This is the first of LXRP’s eight patents pending to be issued and it protects the intellectual property related to infusion of cannabinoid compounds in edible products. There are also two continuation applications filed under this patent which seeks issuance of the remaining seven patents pending pertaining to agents such as psycho-active cannabinoids (THC), fat soluble vitamins such as A, D, E, K, non-steroidal anti-inflammatory drugs (NSAID) such as aspirin or Tylenol and nicotine. Each of these markets is significant in its own right. Again, we are not bragging because we were certainly not alone in holding this view. We are simply pointing out, this expectation was there. To many long term owners of Lexaria, this comes as no surprise. If there was something unexpected, it was that all four agents are covered. Most thought it would probably take another two years the complete this portfolio. But it was a factor in the decision to own the stock.
Quite often investors of all experience levels tend to focus too much on the short term. They think long term factors won’t have an immediate impact so they forget about them. But as we showed these are long term factors that could well have a major impact on the investment values for these two companies. In Canopy’s case, when a company as large as Constellation made a move, it did so above market and triggered additional buying in the market that carried Canopy’s price much higher.
In Lexaria’s case, we pointed out several times that non-cannabis applications of their technology were po-tentially larger than the cannabis potential. (see Lexaria - The Best Cannabis Technology You Can Eat) As we said last week, “…if you look at the four areas that are covered by this Notice of Allowance, cannabis is
by far the fastest growing but also the smallest by a substantial margin. Vitamins are almost 4X as large, NSAIDs are some 7.5X as large and tobacco is nearly 100X as large.” Again a longer term consideration of significant investment value.
If you think you are going to go through a lifetime of investing without ever making a mistake that expectation is your next error. But if you missed Canopy or Lexaria, you should learn from your mistakes. In his book ‘Extraordinary Tennis for the Ordinary Tennis Player’ Dr. Simon Ramo showed that while professional tennis players win points, amateur tennis players lose points. His advice to amateurs to play better tennis was to minimize your mistakes. In other words, just keep getting the ball back any way you can and your opponent will ultimately lose the point.
You can say the same thing about investing. Great investors such as Warren Buffett make wonderful invest-ment decisions that generate above average returns for decades. On October 16, 2008, when the stock markets were crashing and many economists were calling for a recession and a financial meltdown worse than the “Great Depression,” Buffett said in the New York Times, “Buy American. I am.” It was a courageous and great call.
But it’s the kind of decision amateur investors make about as often as amateur tennis players hit a backhand, cross court passing shot. Not very often. If you have invested in the cannabis stocks, you can consider you have already made a great decision. If you haven’t done it yet, there is still time but don’t waste any time. Then from this point forward, concentrate on reducing the number of investment mistakes you make. The lesson from the Canopy/Lexaria examples is don’t let short term factors frighten you into reversing the one great call you have made. After all, “If you don’t profit from your own mistakes, someone else will.”
Gotta agree with you, now is not the time to sell.
Now is the time to buy and hold.
And remember the two biggest mistakes investors make:
They hold their losers too long and sell at the bottom. Use stop losses.
They start to sell off their winners to early and miss the best gains.
The real money will be made by being very patient.
GLTA
Lexaria has some new ads running on BNN TV channel. Slick, well produced, congrats to management for a job well done. Ads feature both John Docherty and Chris Bunka.
No, haven't sold any, waiting for a pullback. Should be under pressure tomorrow, hope to pick up a few more at a better price, before news on Monday.
According to investorshub there are 384.69M shares OS. I don't think this is fully diluted so add any warrants or options OS and you got to be close to half a billion which is their authorized capital.
Float is about 220 million.
https://ih.advfn.com/stock-market/USOTC/greengro-technologies-inc-pc-GRNH/stock-price
Bearish Hanging Man Candlestick Today
What is a 'Hanging Man'
A hanging man is a bearish candlestick pattern that forms at the end of an uptrend. It is created when there is a significant sell-off near the market open, but buyers are able to push this stock back up so that it closes at or near the opening price. Generally, the large sell-off is seen as an early indication that the bulls (buyers) are losing control and demand for the asset is waning.
Hanging Man
BREAKING DOWN 'Hanging Man'
The hanging man formation does not mean that the bulls have definitively lost control, but it may be an early sign that the momentum is decreasing and the direction of the asset may be getting ready to change. Hanging man formations can be more easily identified in intraday charts than daily charts and are a very popular formation used by day traders. If this pattern is found at the end of a downtrend, it is known as a "hammer".
A hanging man candle is identical to the "hammer" candle in its shape but forms at the top of an uptrend indicating a price peak and potential reversion/reversal. While it is traditionally considered a bearish candle, it can also be a continuation candle that sucks in short-sellers and bears and then proceeds to squeeze the price higher. When a pattern becomes too familiar or expected, the market will often form the opposite reaction. This can be expected in a minus sum environment like the financial markets. Therefore, hanging man candles must be approached with several confirmation indicators to determine if it is a bearish reversal signal or a bullish continuation signal in each scenario.
Anatomy of a Hanging Man Candlestick
The candle should have a small body near or at the top of the candle and a large tail or lower shadow that should be at least twice the size of the body. The candle color can be green or red. A red candle close is considered more bearish. The more important detail is the context of the preceding candles leading up to the hanging man and the candles afterward.
Bearish Hanging Man
Typically considered a bearish candlestick, an ideal scenario would be preceding series of at least three or more bullish green candles with higher highs. In the aforementioned structure with a small body and long tail, the hanging man candle should form at the top. The next candle needs to close under the body low, preferably at or below the tail.
The bearish reversal trigger forms when the price falls under the low point of the candle following that hanging man. For example, if XYZ forms a hanging man candle that closes red at $49.50 with a body high of $49.60 with a low of $48.90 (lower tail) and the next candle closes at $49.30 with a high of $49.50 and a low of $48.70 (lower tail), then the reversal confirmation forms when the price falls under $48.79. If the price exceeds the high of the hanging man, then it confirms a bullish uptrend continuation.
Sorry, wrong board, that was Lexaria Bioscience, LXRP.
I'm showing 66,972,000 shares OS.
Chris Bunka owns almost 13 million and the total controlled by insiders, I believe they said, was 21%.
So the total float available would be approx. 52,908,880.
That's not fully diluted, they do have some warrants OS.